Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.30 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.30 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.30 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.30 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.30 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.30 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6719369 | 0.78 | ESR1 (0.42) | TSHRCYP3A4CYP2D6SLC6A2SLC6A4 | |
| SCHEMBL23356101 | 0.77 | CYP3A4 (0.37) | TSHRCYP3A4 | |
| SCHEMBL9588383 | 0.77 | NISCH (0.41) | TSHRCYP3A4CYP2D6SLC6A2SLC6A4 | |
| SCHEMBL7278348 | 0.76 | POLB (0.46) | TSHR | |
| SCHEMBL143126 | 0.74 | CYP2C9 (0.46) | TSHRSLC6A4 | |
| SCHEMBL18243016 | 0.74 | TSHR (0.38) | TSHRCYP3A4CYP2D6SLC6A2SLC6A4 | |
| SCHEMBL5607730 | 0.73 | MIF (0.39) | TSHR | |
| SCHEMBL3807727 | 0.72 | ALDH1A1 (0.46) | TSHRCYP3A4CYP2D6SLC6A2SLC6A4 | |
| SCHEMBL143452 | 0.71 | LMNA (0.46) | — | |
| SCHEMBL8712988 | 0.71 | LMNA (0.46) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240174622-A1 | COMPOUND AND RADIOACTIVE LABELING COMPOUND | NIHON MEDI-PHYSICS CO., LTD. (JP) | 2024-05-30 | — | — | US | disclosed |
| EP-4303213-A1 | COMPOUND AND RADIOACTIVE LABELING COMPOUND | Nihon Medi-Physics Co., Ltd. (JP) | 2024-01-10 | — | — | EP | disclosed |
| US-20230348535-A1 | RADIOMETAL-BINDING COMPOUNDS FOR DIAGNOSIS OR TREATMENT OF PROSTATE SPECIFIC MEMBRANE ANTIGEN-EXPRESSING CANCER | PROVINCIAL HEALTH SERVICES AUTHORITY (CA) | 2023-11-02 | — | — | US | disclosed |
| CN-116940557-A | Compounds and radiolabeled compounds | 日本医事物理股份有限公司 | 2023-10-24 | — | — | CN | disclosed |
| US-20230112418-A1 | COMPOUND AND RADIOACTIVE LABELING COMPOUND | NIHON MEDI-PHYSICS CO., LTD. (JP) | 2023-04-13 | — | — | US | disclosed |
| EP-4116306-A1 | COMPOUND AND RADIOACTIVE LABELING COMPOUND | Nihon Medi-Physics Co., Ltd (JP) | 2023-01-11 | — | — | EP | disclosed |
| CN-115210240-A | Compound and radiolabeled compound | 日本医事物理股份有限公司 | 2022-10-18 | — | — | CN | disclosed |
| US-20200339625-A1 | NOVEL RADIOMETAL-BINDING COMPOUNDS FOR DIAGNOSIS OR TREATMENT OF PROSTATE SPECIFIC MEMBRANE ANTIGEN-EXPRESSING CANCER | PROVINCIAL HEALTH SERVICES AUTHORITY (CA) | 2020-10-29 | — | — | US | disclosed |
| CN-111630059-A | Novel radiometal-binding compounds for the diagnosis or treatment of cancers expressing prostate specific membrane antigen | 省卫生服务机构 | 2020-09-04 | — | — | CN | disclosed |
| EP-3700917-A1 | NOVEL RADIOMETAL-BINDING COMPOUNDS FOR DIAGNOSIS OR TREATMENT OF PROSTATE SPECIFIC MEMBRANE ANTIGEN-EXPRESSING CANCER | Provincial Health Services Authority (CA) | 2020-09-02 | — | — | EP | disclosed |
| WO-2019075583-A1 | NOVEL RADIOMETAL-BINDING COMPOUNDS FOR DIAGNOSIS OR TREATMENT OF PROSTATE SPECIFIC MEMBRANE ANTIGEN-EXPRESSING CANCER | BRITISH COLUMBIA CANCER AGENCY BRANCH (CA) | 2019-04-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200339625-A1 | NOVEL RADIOMETAL-BINDING COMPOUNDS FOR DIAGNOSIS OR TREATMENT OF PROSTATE SPECIFIC MEMBRANE ANTIGEN-EXPRESSING CANCER | FOLH1, KLK3, PSMA3 | TSHR 1821/4885CYP3A4 3991/4885CYP2D6 3410/4885 |
| US-20230348535-A1 | RADIOMETAL-BINDING COMPOUNDS FOR DIAGNOSIS OR TREATMENT OF PROSTATE SPECIFIC MEMBRANE ANTIGEN-EXPRESSING CANCER | FOLH1, KLK3, PSMA3 | TSHR 1657/4885CYP3A4 3742/4885CYP2D6 3211/4885 |
| US-20230112418-A1 | COMPOUND AND RADIOACTIVE LABELING COMPOUND | ALB, TFRC, FABP2 | TSHR 660/4885CYP3A4 3902/4885CYP2D6 4124/4885 |
| US-20240174622-A1 | COMPOUND AND RADIOACTIVE LABELING COMPOUND | PSMA2, PSMA1, PSMA3 | TSHR 2290/4885CYP3A4 3134/4885CYP2D6 4095/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.